摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,6-dihydro-2H-1,4-oxazine-4-oxide | 19690-92-7

中文名称
——
中文别名
——
英文名称
3,6-dihydro-2H-1,4-oxazine-4-oxide
英文别名
2H-1,4-Oxazine, 3,6-dihydro-, 4-oxide;4-oxido-3,6-dihydro-2H-1,4-oxazin-4-ium
3,6-dihydro-2H-1,4-oxazine-4-oxide化学式
CAS
19690-92-7
化学式
C4H7NO2
mdl
——
分子量
101.105
InChiKey
JTPOKGGJICGUIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    365.4±35.0 °C(Predicted)
  • 密度:
    1.11±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.9
  • 重原子数:
    7
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    38
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:cf42a24ebccfefc50ae661d7eec8b9e6
查看

反应信息

  • 作为反应物:
    描述:
    3,6-dihydro-2H-1,4-oxazine-4-oxide三氯化铁 作用下, 以 为溶剂, 反应 2.0h, 生成 4-hydroxymorpholin-3-one
    参考文献:
    名称:
    亚硝基。第九部分 杂环硝酮2,3-二氢-1,4-恶嗪4-氧化物的合成与反应
    摘要:
    通过光谱和环加成研究确定,在氯仿和4-羟基吗啉水溶液中的溶液经过各种氧化剂处理后,可生成2,3-二氢-1,4-恶嗪4-氧化物(IV)。当除去溶剂时,杂环硝酮(IV)产生了据信具有链型结构(X)的聚合物。硝酮(IV)作为还原剂的典型硝酮。它被芳基肼和氯化铁氧化。通过反应性π键系统,它形成了1,3-环加成产物,其结构已通过分析和光谱数据确定。
    DOI:
    10.1039/j39680002423
  • 作为产物:
    描述:
    吗啉 在 oxaziridinium tetrafluoroborate derived from N-methyl-1,2,3,4-tetrahydroisoquinoline 作用下, 以80%的产率得到3,6-dihydro-2H-1,4-oxazine-4-oxide
    参考文献:
    名称:
    四氟硼酸叔胺和亚胺的作用
    摘要:
    衍生自二氢异喹啉的恶唑烷鎓盐1是向伯胺的氧转移试剂,伯胺可导致亚硝基衍生物(如果R =烷基)或硝基化合物(如果R =芳基),叔胺导致N-氧化物,仲胺和亚胺导致到相应的硝酮。
    DOI:
    10.1016/s0040-4020(01)89569-7
点击查看最新优质反应信息

文献信息

  • Seyferth-Gilbert Homologation as a Route to<sup>18</sup>F-Labeled Building Blocks: Preparation of Radiofluor­inated Phenylacetylenes and Their Application in PET Chemistry
    作者:Philipp Krapf、Raphael Richarz、Elizaveta A. Urusova、Bernd Neumaier、Boris D. Zlatopolskiy
    DOI:10.1002/ejoc.201501377
    日期:2016.1
    A convenient method for the preparation of hitherto unknown ([18F]fluorophenyl)acetylenes ([18F]FPAs) using the Seyferth–Gilbert homologation is reported. The novel building blocks were efficiently prepared from easily accessible [18F]fluorobenzaldehydes by using the Bestmann–Ohira reagent. High radiochemical yields and excellent radiochemical purities were achieved within only 20 min of reaction time;
    报道了一种使用 Seyferth-Gilbert 同源性制备迄今为止未知的 ([18F] 氟苯基) 乙炔 ([18F]FPAs) 的便捷方法。通过使用 Bestmann-Ohira 试剂,从易于获得的 [18F] 氟苯甲醛有效地制备了新型构件。仅在 20 分钟的反应时间内即可获得高放射化学产率和优异的放射化学纯度;通过使用不同的环加成和交叉偶联反应,2-和 4-[18F]FPA 被应用于制备放射性氟化杂环。此外,这些构建块还用于制备三种新型 PET 示踪剂。因此,以高放射化学产率获得了人工放射性氟化保护的氨基酸 [18F]10、COX-2 特异性配体 [18F]14 和 PSMA 选择性抑制剂 [18F]16。
  • Mannich‐type Reactions of Cyclic Nitrones: Effective Methods for the Enantioselective Synthesis of Piperidine‐containing Alkaloids
    作者:Vladislav G. Lisnyak、Tessa Lynch‐Colameta、Scott A. Snyder
    DOI:10.1002/anie.201809799
    日期:2018.11.12
    dozens of biologically active 2-substituted and 2,6-disubstituted piperidines, only a limited number of approaches exist for their synthesis. Herein is described two Mannich-type additions to nitrones, one using β-ketoacids under catalyst-free conditions and another using methyl ketones in the presence of chiral thioureas, which can generate a broad array of such 2-substituted materials, as well as other
    尽管有数十种具有生物活性的2取代和2,6-二取代的哌啶,但仅存在数量有限的合成方法。本文描述了对硝酮的两种曼尼希型加成反应,一种在无催化剂条件下使用β-酮酸,另一种在手性硫脲存在下使用甲基酮,可以生成大量此类2-取代的物质,以及其他β-N-羟基-氨基酮形式的环变体。两种方法都有广泛的应用范围,后者提供的产品具有高对映选择性(最高98%)。这些方法的结合以及其他关键步骤,使2,6-二取代哌啶生物碱(-)-小叶碱和(-)-sedinone的8步总合成成为可能。
  • Cyclic nitrone-ethene cycloaddition reactions
    作者:Herman P. Perzanowski、Said S. Al-Jaroudi、Mohamed I.M. Wazeer、Sk.Asrof Ali
    DOI:10.1016/s0040-4020(97)00760-6
    日期:1997.8
    several cyclic nitrones afforded [n,3,0]heterobicyclicalkanes devoid of any substituents in the ring skeleton. These fused ring systems with a bridgehead nitrogen, capable of undergoing nitrogen inversion, allowed us to determine the stereochemistry of the ring fusion and the thermodynamic stability of the cis, trans isomers. Some of the cycloadducts on peracid induced ring opening gave a new series
    将乙烯加成到几个环状硝基上,得到环骨架中没有任何取代基的[n,3,0]杂双环烷烃。这些带有桥头氮的稠合环系统能够进行氮转化,从而使我们能够确定环稠合的立体化学和顺式,反式异构体的热力学稳定性。过酸诱导的开环上的某些环加合物产生了一系列新的硝酮,其能够进行进一步的环加成反应。
  • 异噁唑琳和异噁唑烷取代的青蒿素衍生物、其 制备方法及应用
    申请人:中国科学院上海药物研究所
    公开号:CN106146537B
    公开(公告)日:2021-03-19
    本发明提供了一种含异噁唑琳和异噁唑烷取代的青蒿素衍生物、其制备方法及应用,具体地,本发明提供了一种如下式I所示的化合物。其中,各基团的定义如说明书中所述。本发明化合物具有肿瘤细胞增殖抑制活性,且可以用于制备肿瘤细胞增殖相关的疾病。
  • Photosensitized single electron transfer oxidation of N-hydroxylamines: A convenient synthesis of cyclic nitrones
    作者:G Pandey、G Kumaraswamy、A Krishna
    DOI:10.1016/s0040-4039(00)96172-0
    日期:1987.1
    Photolysis of N-hydroxylamines of type in the presence of 1,4-dicyanonaphthalene (DCN) as an electron acceptor gave high yields of nitrones . Crude nitrones have been trapped by 1,3-dipolar cycloaddition reaction with dimethyl fumarate. Mechanistic pathways have also been discussed.
    在1,4-二氰基萘(DCN)作为电子受体的存在下,N型羟胺的光解产生了高产率的硝酮。粗硝酮已通过与富马酸二甲酯的1,3-偶极环加成反应被捕集。还讨论了机械途径。
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol